Literature DB >> 8529132

Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck.

M Gapany1, R A Faust, S Tawfic, A Davis, G L Adams, K Ahmed.   

Abstract

BACKGROUND: Protein kinase CK2 (also known as casein kinase 2) is a messenger-independent protein serine/threonine kinase ubiquitously distributed in eukaryotes. CK2 has been found to phosphorylate a wide variety of cytosolic and nuclear substrates which are intimately involved in regulation of DNA, RNA, and protein synthesis, and differentiation. We therefore addressed the hypothesis that malignant transformation of upper aerodigestive tract mucosa to squamous cell carcinoma of the head and neck (SCCHN) might be associated with altered CK2 activity.
MATERIALS AND METHODS: To this end, we subjected surgical specimens of SCCHN tumors and of normal oropharyngeal mucosa to subcellular fractionation. We then quantitated CK2 activity in cytosol and nuclei of these specimens using a CK2-specific peptide substrate (Arg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu).
RESULTS: We found that CK2 activity was significantly elevated in both nuclear (p < 0.0005) and cytosolic (p < 0.0034) compartments of SCCHN tumors, relative to normal oropharyngeal mucosa. Moreover, CK2 activity in the cellular cytosolic fraction of SCCHN tumors was associated with less differentiated histologic grade (p < 0.037), positive nodal metastatic status (p < 0.056), and a poor clinical outcome (p < 0.028). Kaplan-Meier cumulative survival analysis revealed greatly reduced survival in the high-CK2 activity patient group, with high statistical significance (p < 0.023).
CONCLUSIONS: These preliminary data reveal that malignant transformation of the upper aerodigestive tract mucosa is associated with altered CK2 activity. The results further suggest that dysregulation of this protein kinase may play a significant role in the pathobiology of SCCHN, and that CK2 activity may be a prognostic indicator in this malignancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529132      PMCID: PMC2229971     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  23 in total

1.  Cancer statistics, 1990.

Authors:  E Silverberg; C C Boring; T S Squires
Journal:  CA Cancer J Clin       Date:  1990 Jan-Feb       Impact factor: 508.702

Review 2.  Dysplasia, in situ carcinoma, and progression to invasive squamous cell carcinoma of the upper aerodigestive tract.

Authors:  J D Crissman; R J Zarbo
Journal:  Am J Surg Pathol       Date:  1989       Impact factor: 6.394

3.  Altered antigen expression predicts outcome in squamous cell carcinoma of the head and neck.

Authors:  G T Wolf; T E Carey; S P Schmaltz; K D McClatchey; J Poore; L Glaser; D J Hayashida; S Hsu
Journal:  J Natl Cancer Inst       Date:  1990-10-03       Impact factor: 13.506

4.  Prognostic factors of neck node metastasis.

Authors:  G B Snow; A A Annyas; E A van Slooten; H Bartelink; A A Hart
Journal:  Clin Otolaryngol Allied Sci       Date:  1982-06

5.  Activation of casein kinase II in response to insulin and to epidermal growth factor.

Authors:  J Sommercorn; J A Mulligan; F J Lozeman; E G Krebs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue.

Authors:  U Münstermann; G Fritz; G Seitz; Y P Lu; H R Schneider; O G Issinger
Journal:  Eur J Biochem       Date:  1990-04-30

7.  Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

Authors:  D M Shin; J Y Ro; W K Hong; W N Hittelman
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

Review 8.  Cancer incidence and mortality trends among whites in the United States, 1947-84.

Authors:  S S Devesa; D T Silverman; J L Young; E S Pollack; C C Brown; J W Horm; C L Percy; M H Myers; F W McKay; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

9.  Growth stimulus-mediated differential translocation of casein kinase 2 to the nuclear matrix. Evidence based on androgen action in the prostate.

Authors:  S Tawfic; K Ahmed
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

10.  Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle.

Authors:  D C Seldin; P Leder
Journal:  Science       Date:  1995-02-10       Impact factor: 47.728

View more
  51 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

2.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

3.  Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

Authors:  Fatima Qaiser; Janeen H Trembley; Sarah Sadiq; Iqbal Muhammad; Rubina Younis; Shoaib Naiyar Hashmi; Badar Murtaza; Thomas S Rector; Abdul Khaliq Naveed; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

4.  Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.

Authors:  Ming Yu; Jason Yeh; Carter Van Waes
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

Review 5.  Protein kinase CK2--a key suppressor of apoptosis.

Authors:  Kashif A Ahmad; Guixia Wang; Gretchen Unger; Joel Slaton; Khalil Ahmed
Journal:  Adv Enzyme Regul       Date:  2008-04-30

6.  B23 is a downstream target of polyamine-modulated CK2.

Authors:  Kathryn Lawson; Laura Larentowicz; Lisa Laury-Kleintop; Susan K Gilmour
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

7.  Response of cancer cells to molecular interruption of the CK2 signal.

Authors:  H Wang; A Davis; S Yu; K Ahmed
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

8.  Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Authors:  Janeen H Trembley; Gretchen M Unger; Vicci L Korman; Diane K Tobolt; Zygmunt Kazimierczuk; Lorenzo A Pinna; Betsy T Kren; Khalil Ahmed
Journal:  Cancer Lett       Date:  2011-10-12       Impact factor: 8.679

9.  Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Authors:  Gretchen M Unger; Betsy T Kren; Vicci L Korman; Tyler G Kimbrough; Rachel I Vogel; Frank G Ondrey; Janeen H Trembley; Khalil Ahmed
Journal:  Mol Cancer Ther       Date:  2014-05-27       Impact factor: 6.261

Review 10.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.